Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by Retired_Investoron May 25, 2013 11:50pm
263 Views
Post# 21442238

Close out NAV

Close out NAV

I think the close out NAV is closer to $1.90 to $2.00.  The Company has about $26 million or $1.30 per share in cash and will generate cash through close out.  But close out costs are $6 million about 15 months from now.  Cash flow will be about $1.5 million a month or a total of $22.5 million if the Oakville plant ran at capacity through that time, but in all likelihood it will shutdown for its normal 2 weeks in July of this year and again next year, and cash usage during the 2 July's is likely $1 million instead of $3 million generation, so think of $18.5 million generation until the plants shut, bring the total to $44.5 million.  Head office shut down costs are over and above the $6 million for Oakville, and will come to about $3 million I expect.  As the shutdown approaches and Ford is launching its new vehicles in Oakville, expect volumes to taper off for a the last few weeks Automodular is operating, with lost revenue of $3 to $4 million.  I come up with a final tally of about $38.5 to $39.5 million or $1.90 to $2.00 per share.  Any GM settlement should add something, unless of course GM is the successful party, in which case AM will have to pay GM a million or two of costs.

That is all assuming things run smoothly.  If there are any setbacks they come right out of the equation and realized NAV will be less.  I think any price over $1.40 to $1.50 right now is a bad bet.

Bullboard Posts